Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

Oligonucleotide therapeutics in cancer.

Wan J, Bauman JA, Graziewicz MA, Sazani P, Kole R.

Cancer Treat Res. 2013;158:213-33. doi: 10.1007/978-3-642-31659-3_9.

PMID:
24222360
[PubMed - in process]
2.

RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Kole R, Krainer AR, Altman S.

Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40. doi: 10.1038/nrd3625. Review.

PMID:
22262036
[PubMed - indexed for MEDLINE]
3.

Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy.

Sazani P, Ness KP, Weller DL, Poage DW, Palyada K, Shrewsbury SB.

Int J Toxicol. 2011 May;30(3):313-21. doi: 10.1177/1091581811403505. Epub 2011 May 3.

PMID:
21540336
[PubMed - indexed for MEDLINE]
4.

Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice.

Sazani P, Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury AS.

Int J Toxicol. 2011 May;30(3):322-33. doi: 10.1177/1091581811403504. Epub 2011 May 3.

PMID:
21540335
[PubMed - indexed for MEDLINE]
5.

Safety pharmacology and genotoxicity evaluation of AVI-4658.

Sazani P, Weller DL, Shrewsbury SB.

Int J Toxicol. 2010 Mar-Apr;29(2):143-56. doi: 10.1177/1091581809359206. Epub 2010 Jan 28.

PMID:
20110565
[PubMed - indexed for MEDLINE]
6.

Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo.

Mellbye BL, Weller DD, Hassinger JN, Reeves MD, Lovejoy CE, Iversen PL, Geller BL.

J Antimicrob Chemother. 2010 Jan;65(1):98-106. doi: 10.1093/jac/dkp392. Epub .

PMID:
19884121
[PubMed - indexed for MEDLINE]
Free Article
7.

Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.

Moulton HM, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R.

Ann N Y Acad Sci. 2009 Sep;1175:55-60. doi: 10.1111/j.1749-6632.2009.04976.x.

PMID:
19796077
[PubMed - indexed for MEDLINE]
8.

Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.

Mourich DV, Iversen PL.

Curr Opin Mol Ther. 2009 Apr;11(2):124-32. Review.

PMID:
19330718
[PubMed - indexed for MEDLINE]
9.

RNA-based therapeutics--from design to the clinic.

Iversen P.

Curr Opin Mol Ther. 2009 Apr;11(2):107. No abstract available.

PMID:
19330715
[PubMed - indexed for MEDLINE]
10.

Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis.

Mourich DV, Jendrzejewski JL, Marshall NB, Hinrichs DJ, Iversen PL, Brand RM.

J Invest Dermatol. 2009 Aug;129(8):1945-53. doi: 10.1038/jid.2009.16. Epub 2009 Feb 19.

PMID:
19225545
[PubMed - indexed for MEDLINE]
Free Article
11.

Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo.

Mellbye BL, Puckett SE, Tilley LD, Iversen PL, Geller BL.

Antimicrob Agents Chemother. 2009 Feb;53(2):525-30. doi: 10.1128/AAC.00917-08. Epub 2008 Nov 17.

PMID:
19015356
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.

Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, Iversen PL, Kinney RM.

J Antimicrob Chemother. 2008 Sep;62(3):555-65. doi: 10.1093/jac/dkn221. Epub 2008 Jun 19.

PMID:
18567576
[PubMed - indexed for MEDLINE]
Free Article
13.

Antisense technologies--Cambridge Health Institute Conference.

Iversen P.

IDrugs. 1998 Sep;1(5):538-40.

PMID:
18465593
[PubMed]
14.

Nucleic acid-based inhibition of flavivirus infections.

Stein DA, Shi PY.

Front Biosci. 2008 Jan 1;13:1385-95. Review.

PMID:
17981637
[PubMed - indexed for MEDLINE]
15.

Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.

Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV.

J Immunol Methods. 2007 Aug 31;325(1-2):114-26. Epub 2007 Jul 27.

PMID:
17673254
[PubMed - indexed for MEDLINE]
16.

Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.

Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, Moulton HM.

Nucleic Acids Res. 2007;35(15):5182-91. Epub 2007 Aug 1.

PMID:
17670797
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.

Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, Wilton SD, Buchmeier MJ, Lebleu B, Iversen PL.

Biochem Soc Trans. 2007 Aug;35(Pt 4):826-8. Review.

PMID:
17635157
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL.

Bioconjug Chem. 2007 Jul-Aug;18(4):1325-31. Epub 2007 Jun 21.

PMID:
17583927
[PubMed - indexed for MEDLINE]
19.

Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM.

Bioconjug Chem. 2007 Jan-Feb;18(1):50-60.

PMID:
17226957
[PubMed - indexed for MEDLINE]
20.

Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.

Tilley LD, Mellbye BL, Puckett SE, Iversen PL, Geller BL.

J Antimicrob Chemother. 2007 Jan;59(1):66-73. Epub 2006 Oct 31.

PMID:
17079242
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk